System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Arash Mostaghimi is an expert in Dermatology at Brigham and Women's Hospital (United States). As of October 2026, ScienceLeadR ranks Arash Mostaghimi in the top 1% of experts worldwide for Pyoderma, Hair Diseases and Alopecia. Arash Mostaghimi has authored 479 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 3 of them ongoing. SLR score: 2,009 (community average: 125). How the SLR is computed.

LeadR Profile

Arash Mostaghimi Brigham and Women's Hospital United States
2 009 ScienceLeadR Reputation 2009

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Public Health - Pharmacy - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026
Source: PubMed

Brigham and Women's Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 479

Citations

Citations: 6 494 1st author: 34 Last author: 231 Unique author: 0

Main journals

J Am Acad Dermatol 120
JAMA Dermatol 87
J Invest Dermatol 35
Arch Dermatol Res 18
Dermatol Ther (Heidelb) 18

Best Journals

N Engl J Med 3
BMJ 1
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical Outcomes in a Longitudinal Virtual Dermatology Care Model for Eczema and Psoriasis.
PMID 42858430 — eczema, psoriasis, dermatology		Dermatol Pract Concept20260
Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2.
PMID 42825995 — safety, alopecia areata, therapeutics, alopecia		Dermatol Ther (Heidelb)20260
Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults.
PMID 42684692 — alopecia areata, skin diseases, surveys and questionnaires, research, therapeutics, alopecia		JAMA Dermatol20261
Oropharyngeal ulcers in Yao syndrome with multisystem involvement.
PMID 42624807 — ulcer		Lancet Top journal20260
Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
PMID 42584887 — quality of life, achievement, safety, alopecia areata, skin diseases, drug-related side effects and adverse reactions, adolescent, therapeutics, alopecia		JAMA Dermatol20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 2 2
Phase 1/Phase 2 1
Phase 2/Phase 3 1
Phase 3 1

By status:

Recruiting 4
Completed 1

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006 — safety, alopecia areata, pharmaceutical preparations, proof of concept study, alopecia		Phase 2Recruiting2026
A Study of LY4005130 in Adult Participants With Non Segmental Vitiligo
NCT07533019 — safety, pharmaceutical preparations, vitiligo, proof of concept study		Phase 2Recruiting2026
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240 — safety, alopecia areata, pharmaceutical preparations, tablets, adolescent, therapeutics, alopecia		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS